Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

Inclusion criteria

• . Diagnosis of refractory or relapsed CD7+ acute myeloid leukemia or mixed lineage leukemia was made according to the NCCN 2019.V2 guideline. Refractory AML is defined as a patient who has failed to achieve complete remission after induction therapy. Relapsed AML is defined as the reappearance of blasts (5%) in either peripheral blood or bone marrow. Patient diagnosed with AML should be treated and whose disease failed with at least 2 prior lines of therapies. Patients whose tumor burden ≥5% blasts, or who have persistent positive minimal residual disease (MRD), or have reappearance of extramedullary lesions are also considered eligible;
• . CD7+ expression on tumor cells (CD7 positive blasts ≥50% by flow cytometry);
• . Life expectancy greater than 12 weeks;
• . KPS or Lansky score≥60;
• . HGB≥70g/L (can be transfused);
• . oxygen saturation of blood\>90%;
• . Total bilirubin (TBil)≤3 × upper limit normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal;
• . Informed consent explained to, understood by and signed by patient/guardian

Exclusion criteria